ALKERMES, INC. for ALKERMES, INC.

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments; Awareness of outcomes data and the need for training on all medication assisted treatment; H.R. 7667 & S. 4348 - Prescription Drug User Fee Agreement reauthorization Awareness of need for transparency and patient access within the 340B program H.R.2617 - Consolidated Appropriations Act, 2023

Contacted: Executive Office of the President (EOP); SENATE; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Office of Natl Drug Control Policy (NDCP); Substance Abuse & Mental Health Services Administration (SAMHSA)

Bills named: H.R. 7667 (117th), S. 4348 (117th), H.R. 2617 (117th)

Medicare/Medicaid MMM

Patient access and maintain six protected classes for depressions and schizophrenia under Medicare Part D; Ensure patient access to behavioral health services and treatments through telehealth; H.R. 5376 - Inflation Reduction Act of 2022 - inflation penalty & redesign on Medicare Part D;

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 5376 (117th)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; Expand funding and flexibility to address all substance use disorders;

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); SENATE; Justice, Dept of (DOJ)